Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. (Q53883381)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Michael Khalil

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

C Gneiss

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

A Lutterotti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

R Ehling

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

R Egg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

T Berger

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

F Deisenhammer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

1 October 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

3 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

507-510

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1074OA

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1074OA

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1074OA

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1074OA

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1074OA

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1074OA

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1074OA

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1074OA

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1074OA

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1074OA

10.1191/1352458504MS1074OA

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15471365%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference